Last reviewed · How we verify

NCT04929132: BIRADS

Added Value of Contrast-enhanced Ultrasound for BI RADS 4A Nodules

Status unknown Last updated 18 June 2021
What this trial tests

trial in Ultrasound in 500 participants. Status unknown.

Timeline
1 January 2019
Primary endpoint
30 December 2021
31 December 2021

Quick facts

Lead sponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date1 January 2019
Primary completion30 December 2021
Estimated completion31 December 2021
Sites1 location across China

Conditions studied

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 80, any sex, with Ultrasound or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to investigate the added value of contrast-enhanced ultrasound (CEUS) for differentiating low risk patients with breast nodules categorized as 4A using the Breast Imaging Reporting and Data System (BI-RADS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ultrasound

Currently open trials in the same condition.

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04929132.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing